Novartis is set to partner with The National Health Service (NHS) England, a publicly funded national healthcare system in the UK, to address cardiovascular disease (CVD).

According to NHS Long Term Plan, cardiovascular disease has been identified as a clinical priority and a condition where lives can be saved over the next 10 years.

Novartis chief executive officer Vas Narasimhan said: “Novartis has a unique opportunity with inclisiran to open up a new chapter in the treatment of cardiovascular disease, the world’s leading cause of mortality and disability.

“We’re confident that innovative approaches like this will enable us to accelerate access timelines, deliver on our broader commitment to generating leading scientific evidence, and ensure continuous improvement in manufacturing efficiency and optimization.”

The Medicines Company has negotiated and signed the current Memorandums of Understanding (MOUs) for the collaboration before it was acquired by Novartis.

The current proposal is aimed at establishing collaboration, encompassing three projects that tackle the challenge of CVD and to provide enhanced opportunities for life science sector development in the UK.

Inclisiran is the first cholesterol-lowering therapy, currently under Phase III development

Novartis said that its investigational drug inclisiran is currently under Phase III development for secondary prevention patients, and it intends to submit the drug to European Medicines Agency (EMA) in the first quarter 2020, for regulatory approval.

The first proposal includes providing inclisiran to secondary prevention ASCVD patients, through a population-level agreement, once the regulatory approval and the National Institute for Health and Care Excellence (NICE) assessment are completed.

The company said that subjecting high-risk population to inclisiran would help NHS meeting its long-term commitment to preventing 150,000 cardiovascular deaths within 10 years.

The second proposal includes conducting a large-scale clinical trial to assess the use of inclisiran to patients at high risk of having their first cardiac event (primary prevention).

The final proposal includes the creation of a consortium for manufacturing synergies to improve the UK’s manufacture of oligonucleotide medicines, including inclisiran.